Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

February 2016; 3 (1) ArticleOpen Access

Vasculitic neuropathy following exposure to minocycline

John M. Baratta, P. James B. Dyck, Patricio Brand, Pariwat Thaisetthawatkul, Peter J. Dyck, JaNean K. Engelstad, Brent Goodman, Chafic Karam
First published November 12, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000180
John M. Baratta
From the Departments of Physical Medicine & Rehabilitation (J.M.B.) and Neurology (C.K.), The University of North Carolina, Chapel Hill; the Department of Neurology (P.J.B.D., P.B., P.J.D., J.K.E.), Mayo Clinic, Rochester, MN; the Department of Neurological Sciences (P.T.), University of Nebraska Medical Center, Omaha; and the Department of Neurology (B.G.), Mayo Clinic, Scottsdale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. James B. Dyck
From the Departments of Physical Medicine & Rehabilitation (J.M.B.) and Neurology (C.K.), The University of North Carolina, Chapel Hill; the Department of Neurology (P.J.B.D., P.B., P.J.D., J.K.E.), Mayo Clinic, Rochester, MN; the Department of Neurological Sciences (P.T.), University of Nebraska Medical Center, Omaha; and the Department of Neurology (B.G.), Mayo Clinic, Scottsdale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricio Brand
From the Departments of Physical Medicine & Rehabilitation (J.M.B.) and Neurology (C.K.), The University of North Carolina, Chapel Hill; the Department of Neurology (P.J.B.D., P.B., P.J.D., J.K.E.), Mayo Clinic, Rochester, MN; the Department of Neurological Sciences (P.T.), University of Nebraska Medical Center, Omaha; and the Department of Neurology (B.G.), Mayo Clinic, Scottsdale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pariwat Thaisetthawatkul
From the Departments of Physical Medicine & Rehabilitation (J.M.B.) and Neurology (C.K.), The University of North Carolina, Chapel Hill; the Department of Neurology (P.J.B.D., P.B., P.J.D., J.K.E.), Mayo Clinic, Rochester, MN; the Department of Neurological Sciences (P.T.), University of Nebraska Medical Center, Omaha; and the Department of Neurology (B.G.), Mayo Clinic, Scottsdale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. Dyck
From the Departments of Physical Medicine & Rehabilitation (J.M.B.) and Neurology (C.K.), The University of North Carolina, Chapel Hill; the Department of Neurology (P.J.B.D., P.B., P.J.D., J.K.E.), Mayo Clinic, Rochester, MN; the Department of Neurological Sciences (P.T.), University of Nebraska Medical Center, Omaha; and the Department of Neurology (B.G.), Mayo Clinic, Scottsdale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JaNean K. Engelstad
From the Departments of Physical Medicine & Rehabilitation (J.M.B.) and Neurology (C.K.), The University of North Carolina, Chapel Hill; the Department of Neurology (P.J.B.D., P.B., P.J.D., J.K.E.), Mayo Clinic, Rochester, MN; the Department of Neurological Sciences (P.T.), University of Nebraska Medical Center, Omaha; and the Department of Neurology (B.G.), Mayo Clinic, Scottsdale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brent Goodman
From the Departments of Physical Medicine & Rehabilitation (J.M.B.) and Neurology (C.K.), The University of North Carolina, Chapel Hill; the Department of Neurology (P.J.B.D., P.B., P.J.D., J.K.E.), Mayo Clinic, Rochester, MN; the Department of Neurological Sciences (P.T.), University of Nebraska Medical Center, Omaha; and the Department of Neurology (B.G.), Mayo Clinic, Scottsdale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chafic Karam
From the Departments of Physical Medicine & Rehabilitation (J.M.B.) and Neurology (C.K.), The University of North Carolina, Chapel Hill; the Department of Neurology (P.J.B.D., P.B., P.J.D., J.K.E.), Mayo Clinic, Rochester, MN; the Department of Neurological Sciences (P.T.), University of Nebraska Medical Center, Omaha; and the Department of Neurology (B.G.), Mayo Clinic, Scottsdale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Vasculitic neuropathy following exposure to minocycline
John M. Baratta, P. James B. Dyck, Patricio Brand, Pariwat Thaisetthawatkul, Peter J. Dyck, JaNean K. Engelstad, Brent Goodman, Chafic Karam
Neurol Neuroimmunol Neuroinflamm Feb 2016, 3 (1) e180; DOI: 10.1212/NXI.0000000000000180

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1627

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective: To report 3 patients with minocycline-induced autoimmunity resulting in peripheral nerve vasculitis.

Methods: We report 3 patients who, during minocycline treatment for acne vulgaris, developed subacute onset of pain and weakness caused by vasculitis in single and multiple mononeuropathy patterns.

Results: Each patient underwent either a nerve or muscle biopsy that confirmed vasculitis. One patient additionally developed systemic symptoms (including fever, fatigue, and night sweats) and another had a posterior circulation stroke. Symptoms developed with either early or prolonged use of minocycline. Despite withdrawal of minocycline, patients needed long-term immunotherapy to gain neurologic improvement.

Conclusions: Our findings suggest that the typical neuropathy associated with minocycline use is painful single or multiple mononeuropathy due to peripheral nerve vasculitis, which may also be accompanied by presumed CNS vasculitis (presenting as stroke).

GLOSSARY

ANA=
antinuclear antibody

Minocycline is a synthetic tetracycline derivative commonly used for its broad-spectrum antibiotic properties, such as in the treatment of acne vulgaris. Prior reports have demonstrated an association between minocycline exposure and development of autoimmune syndromes, such as serum sickness, drug-induced lupus, autoimmune hepatitis, and systemic vasculitis.1 There are additionally several previously reported cases of minocycline-associated vasculitic neuropathy as part of a systemic, drug-induced, lupus-like,2 or polyarteritis nodosa–like syndrome.3 In this case series, we describe 3 patients, 1 previously reported,4 who developed a stereotypical syndrome of painful single or multiple mononeuropathy following minocycline exposure. These conditions were sometimes associated with systemic symptoms (such as fevers and night sweats) and with posterior circulation strokes.

CASE REPORTS

Patient 1.

A 17-year-old otherwise healthy girl awoke with new-onset arm pain, numbness, and weakness in the left ulnar nerve distribution. She had a history of acne for which she had taken minocycline for 3 years. Eleven days after development of the left arm symptoms, she developed numbness over the lateral aspects of the bilateral feet and thighs.

She was seen by an orthopedist who believed she had a compressive left ulnar neuropathy at the elbow and, on day 31 after symptom onset, she underwent a left ulnar nerve transposition. Left arm pain and weakness worsened postoperatively. A month later, the patient developed acute left leg weakness, nausea, and vertigo, which prevented her from walking. On examination, she demonstrated left arm and bilateral ankle dorsiflexion weakness and reduced sensation in the left hand and bilateral feet.

Subsequent brain MRI showed an acute right medial medullary ischemic stroke. Extensive evaluation did not reveal a hypercoagulable state, embolic source, or large artery abnormality. Nerve conduction studies and needle EMG showed diffuse abnormalities within all limbs, which were asymmetric and suggestive of an axonal multiple mononeuropathy or asymmetrical polyradiculoneuropathy. Left upper extremity findings localized to the brachial plexus or multiple peripheral nerves. A brachial plexus MRI showed generalized increased T2 signal intensity throughout the course the left brachial plexus. Antinuclear antibody (ANA) was mildly positive (1:160) and C-reactive protein was elevated (18.4). CSF analysis was normal. Autoimmune and infectious workups were otherwise negative. A left superficial radial nerve biopsy was consistent with necrotizing vasculitis (figure 1).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1 Patient 1 radial nerve biopsy

(A) Hematoxylin & eosin stain of radial nerve demonstrates epineurial nerve large arteriole necrotizing vasculitis. Note the prominent inflammatory cell infiltrate infiltrating and disrupting all layers of the arteriolar wall and the fibrinoid necrosis (arrows). (B) Methylene blue stain of radial nerve demonstrates myelinated fiber degeneration in the center of the fascicle that is typical of ischemic changes (outlined).

Following diagnosis, minocycline was discontinued. The patient was started on IV methylprednisolone and azathioprine. On follow-up several months after discharge, she demonstrated good clinical improvement with regard to pain, strength, and sensation.

Patient 2.

A 33-year-old man was seen in consultation for evaluation of left foot pain and weakness. The patient had a several month history of recurrent episodes of generalized muscle soreness, joint pain, and fatigue. Episodes would last up to several days at a time. The most severe episode occurred in conjunction with a fever (103°F), chills, cold sweats, low back pain radiating to the right testicle, and acute left leg and foot pain and paresthesias. He had been taking minocycline for acne for 2 years. Strength examination was normal apart from mild left foot inversion, ankle plantarflexion, and toe weakness. There was reduced sensation to vibration at the left toe and reduced pinprick at the sole of the left foot.

An ANA was mildly positive (1:160) and a thyroid peroxidase antibody level was elevated (19.34). Autoimmune and infectious workups were otherwise negative. No imaging was performed. Electrophysiology studies demonstrated an isolated left, subacute, primarily axonal, tibial mononeuropathy. A left gastrocnemius muscle biopsy was consistent with necrotizing vasculitis (figure 2).

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2 Patient 2 gastrocnemius muscle biopsy10

Gomori trichrome stain of gastrocnemius muscle biopsy shows large arteriole necrotizing vasculitis.

Following diagnosis, the minocycline was discontinued. The patient was initiated on high-dose oral prednisone and IV cyclophosphamide. At 3-month follow-up after diagnosis, he demonstrated clinical improvement of strength and pain. His constitutional symptoms had fully resolved.

Patient 3 (previously reported).

A 28-year-old woman presented for evaluation of weakness, pain, and paresthesia in the left foot.4 She was previously healthy other than starting minocycline 2 weeks prior for treatment of acne vulgaris. Minocycline was discontinued shortly after symptom onset.

On examination, there was distal left foot weakness involving both peroneal and tibial distributions and diminished sensation in the left sciatic territory. Electrophysiology studies demonstrated a left sciatic mononeuropathy with active denervation in both peroneal and tibial innervated muscles. Serologic testing demonstrated positive ANA and SSA. The remainder of autoimmune and infectious workups was negative. A lumbosacral plexus MRI demonstrated mild increased T2 hyperintensity of the bilateral L4-S1 nerve roots with extension into the femoral and sciatic nerves. A left sural nerve biopsy was consistent with necrotizing vasculitis, with multifocal myelinated fiber loss as well as large and small perivascular inflammatory cell collections in both the endoneurium and epineurium.

After cessation of minocycline, the patient was started on a 1 g per week 12-week IV methylprednisolone treatment session. She was seen in follow-up at 3 months, by which time her strength and gait had returned to normal.

DISCUSSION

Minocycline exposure has recently been associated with the development of several types of systemic autoimmune syndromes.1,–,3 Our 3 cases further demonstrate an association between minocycline exposure and development of both systemic (patient 2, who presented with constitutional symptoms) and possible nonsystemic (patients 1 and 3) vasculitic neuropathies. In each of the 3 cases presented above, minocycline had been initiated for treatment of acne vulgaris before the onset of the neuropathy. The diagnosis of single or multiple vasculitic mononeuropathy in each case was confirmed by nerve or muscle biopsy.

There have also been reports of 2 cases of posterior circulation stroke5,6 and one case of cervical myelopathy in association with vertebral artery vasculitis7 secondary to polyarteritis nodosa–like syndrome related to minocycline use. Patient 1, who sustained an acute right medial medullary ischemic stroke, had no traditional cerebrovascular risk factors and extensive evaluation did not reveal any embolic source or large artery abnormality. Given that the rest of her illness was due to peripheral nerve vasculitis, this patient's stroke was likely due to CNS vasculitis.

The current understanding of minocycline-induced autoimmunity suggests that haptens, which invoke the immune response, may be the product of minocycline processing by neutrophils or hepatocytes.8 Haptens may further bind to degrading enzymes inducing an immune response against those enzymes, such as anti-myeloperoxidase antibodies. Of note, antihistone antibody, which is present in more than 95% of traditional drug-induced lupus, is frequently absent in minocycline-induced autoimmune syndromes.8 The reason for this is unclear.

The timing of minocycline initiation and development of symptoms was variable, ranging from acute (2 weeks in patient 4) to chronic exposures (2–4 years in patients 1–3). Prior reports of systemic minocycline-induced lupus suggest that autoimmunity typically develops after chronic administration of the drug, with Schlienger et al.9 suggesting a median time to onset of 19 months.

Patients who develop a minocycline-induced autoimmune condition typically respond to cessation of the minocycline with administration of oral or IV corticosteroids.8 A steroid-sparing agent, such as cyclophosphamide or azathioprine, may also be added. All 3 of our patients demonstrated clinical improvement following cessation of minocycline and initiation of glucocorticoids with a steroid-sparing agent.

This case series adds to the growing body of literature regarding minocycline-induced autoimmunity. Each of our cases presented in a stereotypical way with the development of pain and weakness in the distribution of single or multiple individual nerves and showed evidence of ischemic injury and vasculitis on nerve and muscle biopsy. One of the patients had a simultaneous posterior circulation stroke. Physicians treating those with neuromuscular conditions should be aware of the possible association between minocycline exposure and the development of both nonsystemic and systemic vasculitic neuropathies and cerebral posterior circulation strokes.

AUTHOR CONTRIBUTIONS

John M. Baratta: conceptualization, data interpretation, manuscript drafting and revision. P. James B. Dyck: conceptualization, data interpretation, manuscript drafting and revision. Patricio Brand: conceptualization, data interpretation. Pariwat Thaisetthawatkul: conceptualization, data interpretation, manuscript drafting and revision. Peter J. Dyck: conceptualization, data interpretation, manuscript drafting and revision. JaNean K. Engelstad: data interpretation. Brent Goodman: conceptualization, data interpretation. Chafic Karam: conceptualization, data interpretation, manuscript drafting and revision.

STUDY FUNDING

No targeted funding.

DISCLOSURE

J.M. Baratta reports no disclosures. P.J.B. Dyck is an associate editor for Journal of Neurology, Neurosurgery and Psychiatry. P. Brand and P. Thiasetthawatkul report no disclosures. P.J. Dyck was an associate editor for Diabetes, and received research support from Pfizer, Isis Pharmaceuticals, Anylam Pharmaceuticals, NIH, FDA, and NCRR. JaNean Englestad received royalties from Saunders. B.P. Goodman reports no disclosures. C. Karam serves as Neurology® WriteClick® deputy editor, was on the editorial board for Neurology Resident and Fellow Section, received speaker honoraria from NuFACTOR, and has consulted for Lundbeck. Go to Neurology.org/nn for full disclosure forms.

Footnotes

  • Funding information and disclosures are provided at the end of the article. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was paid by UNC Neurology.

  • Received June 19, 2015.
  • Accepted in final form October 6, 2015.
  • © 2015 American Academy of Neurology

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

REFERENCES

  1. 1.↵
    1. Elkayam O,
    2. Yaron M,
    3. Caspi D
    . Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum 1999;28:392–397.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Graham L,
    2. Bell A
    . Minocycline-associated lupus-like syndrome with ulnar neuropathy and antiphospholipid antibody. Clin Rheumatol 2001;20:67–69.
    OpenUrlPubMed
  3. 3.↵
    1. Ogawa N,
    2. Kawai H,
    3. Yamakawa I,
    4. Sanada M,
    5. Sugimoto T,
    6. Maeda K
    . Case of minocycline-induced vasculitic neuropathy [in Japanese]. Rinsho Shinkeigaku 2010;50:301–305.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Thaisetthawatkul P,
    2. Sundell R,
    3. Robertson CE,
    4. Dyck PJ
    . Vasculitic neuropathy associated with minocycline use. J Clin Neuromuscul Dis 2011;12:231–234.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Kermani TA,
    2. Ham EK,
    3. Camilleri MJ,
    4. Warrington KJ
    . Polyarteritis nodosa-like vasculitis in association with minocycline use: a single-center case series. Semin Arthritis Rheum 2012;42:213–221.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Klaas JP,
    2. Matzke T,
    3. Makol A,
    4. Fulgham JR
    . Minocycline-induced polyarteritis nodosa-like vasculitis presenting as brainstem stroke. J Clin Neurosci 2015;22:904–907.
    OpenUrlPubMed
  7. 7.↵
    1. Garg N,
    2. Altowaijri GH,
    3. Nesbit GM,
    4. Gultekin SH,
    5. Bourdette DN
    . Minocycline-associated vasculitis of extracranial branches of vertebral arteries presenting as myelopathy. Neurol Neuroimmunol Neuroinflamm 2014;1:e7.
    OpenUrl
  8. 8.↵
    1. Schaffer JV,
    2. Davidson DM,
    3. McNiff JM,
    4. Bolognia JL
    . Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris. J Am Acad Dermatol 2001;44:198–206.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Schlienger RG,
    2. Bircher AJ,
    3. Meier CR
    . Minocycline-induced lupus. A systematic review. Dermatology 2000;200:223–231.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Karam C
    . Eye of the storm. Neurology 2015;84:1180.
    OpenUrl

Letters: Rapid online correspondence

  • Author Response to Dr. Shubhakaran
    • Chafic Karam, Assistant Professor, University of North Carolinachafickaram@gmail.com
    • John M. Baratta, P. James B. Dyck, Patricio Brand, Pariwat Thaisetthawatkul, Peter J. Dyck, JaNean K. Engelstad, Brent Goodman
    Submitted November 23, 2015
  • Vasculitis following exposure to minocycline: Role in stroke and multiple sclerosis
    • Khichar Purnaram Shubhakaran, Associate Professor Neurology, Dr. S. N. Medical College, Jodhpurdrkhicharsk@gmail.com
    Submitted November 18, 2015
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • GLOSSARY
    • CASE REPORTS
    • DISCUSSION
    • AUTHOR CONTRIBUTIONS
    • STUDY FUNDING
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Preferences and User Experiences of Wearable Devices in Epilepsy A Systematic Review and Mixed-Methods Synthesis

Dr. Daniel Friedman and Dr. Sharon Chiang

► Watch

Topics Discussed

  • All Immunology
  • All Cerebrovascular disease/Stroke
  • Autoimmune diseases
  • Vasculitis
  • Other cerebrovascular disease/ Stroke

Alert Me

  • Alert me when eletters are published
Neurology - Neuroimmunology Neuroinflammation: 10 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise